VERA
Vera Therapeutics, Inc.
$34.04
-0.31
(-0.90%)
Mkt Cap
2.44B
Volume
418,270
52W Range
18.76-56.05
Sector
Healthcare
Beta
0.95
EPS (TTM)
-5.54
P/E Ratio
-10.86
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (299.62M) | (152.15M) | (95.99M) | (89.06M) | (32.61M) | (53.41M) | (11.85M) |
| EPS | -4.66 | -2.75 | -2.25 | -3.35 | -2.43 | -14.40 | -3.46 |
| Free Cash Flow | (241.73M) | (135.65M) | (92.24M) | (67.66M) | (23.71M) | (34.91M) | (10.41M) |
| FCF / Share | -3.76 | -2.45 | -2.16 | -2.55 | -1.76 | -9.41 | -3.04 |
| Operating CF | (241.10M) | (134.68M) | (92.18M) | (67.60M) | (23.71M) | (34.81M) | (10.29M) |
| Total Assets | 734.73M | 655.68M | 175.55M | 131.44M | 83.75M | 54.55M | 5.38M |
| Total Debt | 77.31M | 54.64M | 53.71M | 31.29M | 4.92M | 2,000 | 132,000 |
| Cash & Equiv | 354.73M | 92.65M | 45.68M | 43.46M | 79.67M | 53.65M | 3.19M |
| Book Value | 604.52M | 577.15M | 101.69M | 76.91M | 69.59M | (89.35M) | (36.55M) |
| Return on Equity | -0.50 | -0.26 | -0.94 | -1.16 | -0.47 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (121.03M) | (91.10M) | (80.29M) | (76.53M) | (51.69M) | (43.42M) | (46.63M) | (33.71M) | (28.38M) | (25.66M) | (20.10M) | (20.16M) |
| EPS | -1.69 | -1.39 | -1.26 | -1.20 | -0.81 | -0.85 | -0.85 | -0.62 | -0.56 | -0.58 | -0.45 | -0.46 |
| Free Cash Flow | (106.67M) | (70.10M) | (62.04M) | (55.01M) | (54.59M) | (39.83M) | (61.99M) | (24.87M) | (33.83M) | (25.21M) | (22.97M) | (17.77M) |
| FCF / Share | -1.49 | -1.09 | -0.97 | -0.86 | -0.86 | -0.73 | -1.13 | -0.45 | -0.66 | -0.57 | -0.52 | -0.40 |
| Operating CF | (106.50M) | (69.99M) | (61.91M) | (54.80M) | (54.41M) | (39.18M) | (36.88M) | (24.78M) | (33.83M) | (25.14M) | (22.97M) | (17.77M) |
| Total Assets | 621.74M | 734.73M | 517.50M | 578.53M | 610.17M | 655.68M | 368.56M | 397.29M | 419.36M | 175.55M | 175.62M | 195.18M |
| Total Debt | 75.03M | 77.31M | 77.22M | 77.55M | 54.47M | 54.64M | 54.91M | 52.83M | 53.26M | 53.71M | 29.52M | 30.09M |
| Cash & Equiv | 114.35M | 354.73M | 57.77M | 49.12M | 55.09M | 92.65M | 27.26M | 25.09M | 69.11M | 45.68M | 27.44M | 33.89M |
| Book Value | 499.70M | 604.52M | 398.88M | 468.28M | 535.00M | 577.15M | 289.06M | 327.87M | 353.54M | 101.69M | 123.71M | 140.52M |
| Return on Equity | -0.24 | -0.15 | -0.20 | -0.16 | -0.10 | -0.08 | -0.16 | -0.10 | -0.08 | -0.25 | -0.16 | -0.14 |
VERA News
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
JPMorgan Chase & Co. Sells 228,182 Shares of Vera Therapeutics, Inc. $VERA
These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of “Moderate Buy” by Brokerages
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year